Hormone response in ovarian cancer: time to reconsider as a clinical target?
about
Hormone Receptors in Serous Ovarian Carcinoma: Prognosis, Pathogenesis, and Treatment ConsiderationsThe Important Roles of Steroid Sulfatase and Sulfotransferases in Gynecological DiseasesHormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium studyThe role of the androgen receptor in ovarian cancer carcinogenesis and its clinical implications.The Importance of Steroid Uptake and Intracrine Action in Endometrial and Ovarian Cancers.Prognostic value of progesterone receptor expression in ovarian cancer: a meta-analysisWhole genome expression profiling of blood cells in ovarian cancer patients -prognostic impact of the CYP1B1, MTSS1, NCALD, and NOP14.Expression and molecular consequences of inhibition of estrogen receptors in granulosa cells of bovine folliclesEstrogen biosynthesis and action in ovarian cancer.Antiprogestins in gynecological diseases.Progesterone action in breast, uterine, and ovarian cancers.Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium.Ovarian mucinous adenocarcinoma with functioning stroma in postmenopausal women: aromatase and SF-1 expressionsIntegrative transcriptomics-based identification of cryptic drivers of taxol-resistance genes in ovarian carcinoma cells: Analysis of the androgen receptor.Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study.Ovarian cancer treatment: The end of empiricism?Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells.Progesterone and FOXO1 signaling: harnessing cellular senescence for the treatment of ovarian cancer.Progestins: pro-senescence therapy for ovarian cancer?Candidate genes and pathways downstream of PAX8 involved in ovarian high-grade serous carcinoma.Hormonal treatment in recurrent and metastatic gynaecological cancers: a review of the current literature.Treatment of ovarian cancer beyond chemotherapy: are we hitting the target?Androgens Are Differentially Associated with Ovarian Cancer Subtypes in the Ovarian Cancer Cohort Consortium.Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens.Interactions between dietary acrylamide intake and genes for ovarian cancer risk.Impact of levonorgestrel-releasing intrauterine system use on the cancer risk of the ovary and fallopian tube.Irregular menses predicts ovarian cancer: Prospective evidence from the Child Health and Development Studies.Differential expression of estrogen receptor subtypes and variants in ovarian cancer: effects on cell invasion, proliferation and prognosis.Endogenous androgens and risk of epithelial invasive ovarian cancer by tumor characteristics in the European Prospective Investigation into Cancer and Nutrition.Hormone receptors expression in ovarian cancer taking into account menopausal status: a retrospective study in Chinese population.The positivity of estrogen receptor and progesterone receptor may not be associated with metastasis and recurrence in epithelial ovarian cancer.Understanding the functional role of genistein in the bone differentiation in mouse osteoblastic cell line MC3T3-E1 by RNA-seq analysis.Estrogen receptor modulators genistein, daidzein and ERB-041 inhibit cell migration, invasion, proliferation and sphere formation via modulation of FAK and PI3K/AKT signaling in ovarian cancer.Nanog interaction with the androgen receptor signaling axis induce ovarian cancer stem cell regulation: studies based on the CRISPR/Cas9 system.
P2860
Q26751021-7C27B79F-91C2-49D8-948D-7F913926086DQ26765913-E9608088-A8B5-411E-ADDE-D544E236A5AFQ33551425-0A8D69CF-D240-4487-A4F2-B54CBF6FAEFBQ33710140-FCB60CD3-3C22-4F8A-A034-3601D1F5851EQ33809605-94B61CDE-45C1-48BD-9477-27A6E4D80EA8Q33829679-7F33A6E3-3AD9-4BEC-AB8C-A73E2D97ED3CQ34100848-3ABA2237-6A39-451C-B072-16AA21A29CE6Q34410743-C0459AA5-765C-4D67-99AF-35E5EC6593AFQ34496401-B0A7E68E-3DEA-481A-B3E2-DBE1F519B837Q34587636-8226080D-6BE1-4478-A59F-A1383BD8A1CEQ35108906-A18A9DB5-1BAB-4997-B73B-9A62E8E4B82DQ36027025-2DCC64AE-2A3E-4F32-A187-99AE2A0AE56FQ36292454-88FC8587-808F-4C9B-9AE3-E8715624B5D0Q36413695-C4ADD099-FBF5-42E0-885F-2E98E399A3D6Q36443891-972D0DB8-7DFF-455E-9033-594C5035E41BQ36554444-93488979-76D1-46AD-83FE-365081A62A6DQ36906210-6F23C85B-F70D-407A-AFAE-C256E17C0B55Q37018208-F1A6B80D-B844-4BC4-83DC-D496F09EAAC9Q37018212-63E5B147-3F58-4A32-85E0-1B88ADD3DE60Q37520401-E3D6E316-5A3C-46CC-8FF9-5C461BED9CE0Q38149813-C965C823-DDA0-444F-800E-AA4EB0D9C613Q38248418-8AC79339-BB9A-4419-8EB0-B7794071E590Q38851593-A3BDC5B4-EC1C-4536-8EE1-07418040F8F0Q39028384-F3D2AAF2-E044-427A-9836-67DE714EBB63Q40251700-65E409D1-BF2D-48A1-972E-79915E193C1CQ40767970-E6F89CCB-18AE-4E0C-A57B-D73B8D49E0F8Q40798586-19FA5B39-D6A4-49AC-8CC5-F27A5231694FQ41585965-6329826A-ED54-4EBB-943E-69FCA1D775D0Q43584802-75943F3F-6CB1-4468-B179-88AC1860176BQ47119695-80692F04-C5CD-4FD9-8F05-0DAB9D2F5F2DQ47132013-1FAD19FE-62C7-47B4-A6B7-88E6CFF90F23Q49831206-5FED80BF-FA1C-4764-94CD-8871A4CC0C9DQ55228036-588D8894-064B-49DF-9A3D-B36A8FFE6E34Q55246092-AF547481-7E1E-4B67-86E5-8B5737129D50
P2860
Hormone response in ovarian cancer: time to reconsider as a clinical target?
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Hormone response in ovarian cancer: time to reconsider as a clinical target?
@en
type
label
Hormone response in ovarian cancer: time to reconsider as a clinical target?
@en
prefLabel
Hormone response in ovarian cancer: time to reconsider as a clinical target?
@en
P2093
P2860
P356
P1476
Hormone response in ovarian cancer: time to reconsider as a clinical target?
@en
P2093
Ashlee L Smith
Francesmary Modugno
Robin Laskey
Steffi Oesterreich
P2860
P304
P356
10.1530/ERC-12-0175
P577
2012-11-09T00:00:00Z